NASDAQ:MBRX Moleculin Biotech - MBRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.24 -0.01 (-0.80%) (As of 02/8/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.24▼$1.2750-Day Range$1.06▼$1.4952-Week Range$0.82▼$2.05Volume14,756 shsAverage Volume47,063 shsMarket Capitalization$35.50 millionP/E RatioN/ADividend YieldN/APrice Target$10.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Moleculin Biotech MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside746.8% Upside$10.50 Price TargetShort InterestHealthy0.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$166,132 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.06) to ($1.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector390th out of 1,026 stocksPharmaceutical Preparations Industry191st out of 504 stocks 3.5 Analyst's Opinion Consensus RatingMoleculin Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.50, Moleculin Biotech has a forecasted upside of 746.8% from its current price of $1.24.Amount of Analyst CoverageMoleculin Biotech has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.28% of the float of Moleculin Biotech has been sold short.Short Interest Ratio / Days to CoverMoleculin Biotech has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Moleculin Biotech has recently decreased by 34.91%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMoleculin Biotech does not currently pay a dividend.Dividend GrowthMoleculin Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MBRX. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Moleculin Biotech this week, compared to 0 articles on an average week.Search Interest2 people have searched for MBRX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Moleculin Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Moleculin Biotech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $166,132.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.70% of the stock of Moleculin Biotech is held by insiders.Percentage Held by InstitutionsOnly 10.43% of the stock of Moleculin Biotech is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Moleculin Biotech are expected to decrease in the coming year, from ($1.06) to ($1.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Moleculin Biotech is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Moleculin Biotech is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMoleculin Biotech has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Moleculin Biotech (NASDAQ:MBRX) StockMoleculin Biotech, Inc. is a clinical stage pharmaceutical company, which engages in the development of treatments for highly resistant cancers and viruses. Its clinical stage drugs include Annamycin, an Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia (AML), and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and AML. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.Read More Receive MBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address MBRX Stock News HeadlinesFebruary 7, 2023 | americanbankingnews.comMoleculin Biotech (NASDAQ:MBRX) Receives New Coverage from Analysts at StockNews.comJanuary 30, 2023 | americanbankingnews.comMoleculin Biotech (NASDAQ:MBRX) Coverage Initiated by Analysts at StockNews.comFebruary 9, 2023 | Investing Trends (Ad)Without Graphite, There Would Be ZERO EV Batteries!Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.January 15, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Achilles Therapeutics (ACHL), Cidara Therapeutics (CDTX) and Moleculin Biotech (MBRX)January 5, 2023 | finance.yahoo.comMoleculin to Present at the Virtual Investor 2023 Companies to Watch EventDecember 21, 2022 | finance.yahoo.comMoleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)December 19, 2022 | finance.yahoo.comIs Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Invest In Growth?December 17, 2022 | markets.businessinsider.comMaxim Group Keeps Their Buy Rating on Moleculin Biotech (MBRX)February 9, 2023 | Investing Trends (Ad)The Lithium "Lie"Did you know each electric car battery requires 220 pounds of graphite – more than lithium, copper, or aluminum? China controls more than 90% of this vital ingredient. But the U.S. just classified graphite as "essential for America's National Defense"... and one little-known company is looking to win big in the energy war with China. December 15, 2022 | finance.yahoo.comMoleculin Biotech's Annamycin In Leukemia Study Shows 80% Overall Response RateDecember 15, 2022 | finance.yahoo.comMoleculin Reports 80% Overall Response Rate in Final Cohort of Phase 1 Single Agent Trial of Annamycin for the Treatment of Acute Myeloid Leukemia (AML)December 7, 2022 | marketwatch.comMoleculin Gets FDA Fast-Track Designation for WP1122 in Glioblastoma Multiforme >MBRXDecember 7, 2022 | markets.businessinsider.comMoleculin Announces FDA Fast Track Designation For WP1122November 15, 2022 | finance.yahoo.comBiotech firm Moleculin touts strong cash position, clinical trials in Q3 earnings callNovember 10, 2022 | finance.yahoo.comMoleculin Reports Third Quarter 2022 Financial Results and Provides Pipeline UpdateNovember 7, 2022 | thestreet.comHow to Invest in BiotechnologyNovember 7, 2022 | finance.yahoo.comMoleculin to Report Third Quarter 2022 Financial Results on November 10, 2022 and Host Inaugural Quarterly Conference Call and WebcastOctober 14, 2022 | finance.yahoo.comMoleculin Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UKSeptember 27, 2022 | msn.comMoleculin Biotech's Potential Antiviral Compound Selected For NIAID-Funded Animal StudiesSeptember 27, 2022 | finance.yahoo.comMoleculin Biotech WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies as Novel Potential AntiviralSeptember 23, 2022 | finance.yahoo.comMoleculin Biotech to Present at the Virtual Investor Innovations in Acute Myeloid Leukemia (AML) Spotlight EventSeptember 8, 2022 | finance.yahoo.comMoleculin Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and CareSeptember 7, 2022 | finance.yahoo.comMoleculin to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 6, 2022 | nasdaq.comMoleculin Biotech Announces Receipt Of Orphan Drug Designation For WP1122 - Quick FactsAugust 19, 2022 | finance.yahoo.comMoleculin Announces Completion of Third Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UKAugust 16, 2022 | seekingalpha.comMoleculin Biotech GAAP EPS of -$0.24August 15, 2022 | finance.yahoo.comMoleculin Reports Second Quarter 2022 Financial Results and Provides Programs UpdateSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address MBRX Company Calendar Last Earnings11/11/2021Today2/09/2023Next Earnings (Estimated)3/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MBRX CUSIPN/A CIK1659617 Webwww.moleculin.com Phone(713) 300-5160FaxN/AEmployees13Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.50 High Stock Price Forecast$16.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+746.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.62% Return on Assets-36.32% Debt Debt-to-Equity RatioN/A Current Ratio8.41 Quick Ratio8.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.76 per share Price / Book0.45Miscellaneous Outstanding Shares28,630,000Free Float27,569,000Market Cap$35.50 million OptionableNot Optionable Beta2.00 Key ExecutivesWalter V. KlempChairman, President & Chief Executive OfficerJonathan P. FosterChief Financial Officer & Executive Vice PresidentRobert ShepardChief Medical Officer-AnnamycinDonald H. PickerChief Scientific OfficerSandra Leta SilbermanChief Medical Officer-New ProductsKey CompetitorsDiaMedica TherapeuticsNASDAQ:DMACBiora TherapeuticsNASDAQ:BIORNovanNASDAQ:NOVNAcer TherapeuticsNASDAQ:ACERApexigenNASDAQ:APGNView All CompetitorsInsiders & InstitutionsWalter V KlempBought 45,000 shares on 11/25/2022Total: $57,600.00 ($1.28/share)Walter V KlempBought 22,500 shares on 11/21/2022Total: $25,875.00 ($1.15/share)Walter V KlempBought 85,213 shares on 11/16/2022Total: $82,656.61 ($0.97/share)View All Insider Transactions MBRX Stock - Frequently Asked Questions Should I buy or sell Moleculin Biotech stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MBRX shares. View MBRX analyst ratings or view top-rated stocks. What is Moleculin Biotech's stock price forecast for 2023? 1 brokers have issued 1 year price objectives for Moleculin Biotech's shares. Their MBRX share price forecasts range from $5.00 to $16.00. On average, they predict the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 746.8% from the stock's current price. View analysts price targets for MBRX or view top-rated stocks among Wall Street analysts. How have MBRX shares performed in 2023? Moleculin Biotech's stock was trading at $1.06 at the beginning of 2023. Since then, MBRX shares have increased by 17.0% and is now trading at $1.24. View the best growth stocks for 2023 here. Are investors shorting Moleculin Biotech? Moleculin Biotech saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 77,200 shares, a decrease of 34.9% from the December 31st total of 118,600 shares. Based on an average daily trading volume, of 101,300 shares, the short-interest ratio is presently 0.8 days. Approximately 0.3% of the company's stock are sold short. View Moleculin Biotech's Short Interest. When is Moleculin Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 24th 2023. View our MBRX earnings forecast. How were Moleculin Biotech's earnings last quarter? Moleculin Biotech, Inc. (NASDAQ:MBRX) issued its earnings results on Thursday, November, 10th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.27) by $0.03. During the same period in the prior year, the company posted ($0.15) earnings per share. When did Moleculin Biotech's stock split? Moleculin Biotech's stock reverse split before market open on Monday, February 1st 2021. The 1-6 reverse split was announced on Friday, January 29th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 29th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. What other stocks do shareholders of Moleculin Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL). What is Moleculin Biotech's stock symbol? Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX." How do I buy shares of Moleculin Biotech? Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Moleculin Biotech's stock price today? One share of MBRX stock can currently be purchased for approximately $1.24. How much money does Moleculin Biotech make? Moleculin Biotech (NASDAQ:MBRX) has a market capitalization of $35.50 million. The company earns $-15,890,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. How can I contact Moleculin Biotech? Moleculin Biotech's mailing address is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. The official website for the company is www.moleculin.com. The company can be reached via phone at (713) 300-5160 or via email at jsalierno@theruthgroup.com. This page (NASDAQ:MBRX) was last updated on 2/9/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.